Advertisement
BEAM vs SANA
Which Stock Would AI Choose? Beam Therapeutics (BEAM) vs. Sana Biotechnology (SANA) Stock Comparison
Key Takeaways
- BEAM is a clinical-stage leader in base editing (a precision gene-editing approach), while SANA is an earlier-stage developer of engineered-cell therapies.
- Both companies are pre-revenue and unprofitable, making them high-risk biotechnology holdings driven primarily by clinical catalysts.
- BEAM holds roughly $1.2 billion in cash supporting operations into mid-2029, a materially longer runway than SANA, which recently extended its runway into mid-2027.
- BEAM plans a biologics license application (BLA) filing for its sickle cell disease (SCD) candidate by the end of 2026, while SANA's key clinical readouts remain further out.
- Recent market momentum has favored BEAM, whereas SANA has traded down year-to-date despite a higher-risk, higher-reward pipeline profile.
- For more on each ticker's developments, explore BEAM Major News and BEAM Today's Price Move, plus SANA Major News and SANA Today's Price Move.
- To see which stocks algorithmic strategies are currently favoring, explore the curated Trending AI Robots page.
Introduction
This stock comparison examines two gene- and cell-therapy developers at very different stages of maturity. Beam Therapeutics (BEAM) has advanced toward regulatory filings with clinical proof-of-concept data, while Sana Biotechnology (SANA) is positioned earlier in development with a broader, more speculative pipeline. Growth-oriented and event-driven investors evaluating relative performance and market positioning in the biotechnology sector may find this comparison useful, particularly those weighing a more de-risked, later-stage story against a higher-risk, higher-potential opportunity.
BEAM Overview and Recent Performance
Beam Therapeutics develops precision genetic medicines using base editing, a technique that rewrites single DNA "letters" without cutting the DNA strand. Its lead programs target sickle cell disease (SCD, an inherited blood disorder) and alpha-1 antitrypsin deficiency (AATD, a genetic liver and lung condition). The company has reported encouraging clinical data for its AATD candidate BEAM-302 and plans to submit a BLA for risto-cel, its SCD therapy, by the end of 2026. In recent weeks, shares have shown notable strength, rising roughly 20% over a three-month stretch on positive pipeline and regulatory progress, though the stock also pulled back after updated BEAM-302 data was viewed as numerically unchanged rather than improved. With roughly $1.2 billion in cash and a runway into mid-2029, BEAM's balance sheet provides meaningful flexibility.
SANA Overview and Recent Performance
Sana Biotechnology focuses on engineered cells as medicines, built around its Hypoimmune platform designed to let transplanted cells evade immune rejection without immunosuppression. Its pipeline includes SC451, a stem-cell-derived pancreatic islet cell therapy for type 1 diabetes, and SG293, an in vivo CAR T (chimeric antigen receptor T-cell) program for B-cell diseases. The company published early data showing transplanted allogeneic beta cells survived without immunosuppression, an important proof-of-concept, but its programs remain preclinical or early clinical. Financially, SANA raised $69 million through an at-the-market equity offering and a Mayo Clinic investment, extending its cash runway into mid-2027. Despite strong analyst price targets, the stock has declined year-to-date, reflecting its earlier-stage risk profile and ongoing cash needs.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and sets of securities they follow. Because market conditions change constantly, only the bots best suited to the current environment earn a place in the curated Trending AI Robots section. This rotating selection helps traders identify algorithmic strategies that are presently performing well across varying volatility and trend regimes. Reviewing the available bots' statistics can offer a data-driven starting point for those exploring automated approaches. To see which strategies are currently trending, visit Trending AI Robots.
Head-to-Head Comparison
The two companies differ most in development stage and financial durability. BEAM is further along, with clinical proof-of-concept and a near-term BLA filing, backed by a substantial cash position that reduces near-term dilution risk. SANA offers broader therapeutic ambition—spanning type 1 diabetes, oncology, and autoimmune disease—but remains largely preclinical, with a shorter runway and recent reliance on equity financing that can pressure the share price. Sector exposure is similar on the surface, yet BEAM skews toward genetic disease with a single enabling technology, while SANA spans multiple cell-engineering modalities. In terms of recent momentum, BEAM has outperformed, while SANA's year-to-date decline reflects elevated uncertainty. Risk factors diverge accordingly: BEAM faces execution and regulatory risk on specific programs, whereas SANA carries higher scientific and financing risk with potentially larger optionality.
Tickeron AI Verdict
Based on observable factors—trend consistency, financial stability, catalyst proximity, and relative positioning—Tickeron's AI would currently lean toward BEAM. The stock's steadier recent momentum, longer cash runway, and nearer-term regulatory catalysts present a more defined path than SANA's earlier-stage pipeline. That said, this is a probabilistic assessment rather than a definitive ranking; SANA's broader platform and higher analyst upside targets could appeal to investors with greater risk tolerance. Relative positioning can shift quickly in biotechnology as clinical data and financing developments unfold.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and SANA is a StrongBuy.
BEAM in upward trend: 10-day moving average moved above 50-day moving average on November 03, 2026
The 10-day moving average for BEAM crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BEAM as a result. In 66 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
BEAM moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 198 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for BEAM moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 56 cases where BEAM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
BEAM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.555) is normal, around the industry mean (3.498). P/E Ratio (-38.275) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SANA in -11.77% downward trend, sliding for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SANA declined for three days, in 285 of 321 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
SANA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SANA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SANA's RSI Oscillator exited the oversold zone, 37 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SANA as a result. In 61 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for SANA just turned positive on October 26, 2026. Looking at past instances where SANA's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where SANA advanced for three days, in 186 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.590) is normal, around the industry mean (3.498). P/E Ratio (-3.160) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. SANA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SANA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BEAM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 92 | |
PRICE GROWTH RATING 1..100 | 53 | |
P/E GROWTH RATING 1..100 | 46 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BEAM | SANA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 81% |
| MACD ODDS (%) | N/A | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 89% |
| Advances ODDS (%) | 1 day ago 76% | 1 day ago 79% |
| Declines ODDS (%) | 9 days ago 84% | 9 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 84% |
| Aroon ODDS (%) | N/A | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAM’s FA Score shows that 1 FA rating(s) are green while SANA’s FA Score has 1 green FA rating(s).
- BEAM’s FA Score: 1 green, 4 red.
- SANA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAM’s TA Score shows that 4 TA indicator(s) are bullish while SANA’s TA Score has 5 bullish TA indicator(s).
- BEAM’s TA Score: 4 bullish, 4 bearish.
- SANA’s TA Score: 5 bullish, 3 bearish.
Price Growth
BEAM (@Biotechnology) experienced а +4.45% price change this week, while SANA (@Biotechnology) price change was +2.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was -8.97%, and the average quarterly price growth was +85.13%.
Reported Earning Dates
BEAM is expected to report earnings on Mar 02, 2027.
SANA is expected to report earnings on Mar 23, 2027.
Industries' Descriptions
@Biotechnology (+2.23% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BEAM and
Correlation & Price change
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
|---|---|---|---|---|
| BEAM | 100% | +2.31% | ||
| CRSP - BEAM | 77% Closely correlated | -0.06% | ||
| EDIT - BEAM | 67% Closely correlated | +7.00% | ||
| NTLA - BEAM | 67% Closely correlated | +6.70% | ||
| PRME - BEAM | 64% Loosely correlated | -7.53% | ||
| RXRX - BEAM | 60% Loosely correlated | +8.10% | ||
More | ||||
SANA and
Correlation & Price change
A.I.dvisor indicates that over the last year, SANA has been loosely correlated with EDIT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SANA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SANA | 1D Price Change % | ||
|---|---|---|---|---|
| SANA | 100% | +4.01% | ||
| EDIT - SANA | 59% Loosely correlated | +7.00% | ||
| CRSP - SANA | 58% Loosely correlated | -0.06% | ||
| RCKT - SANA | 57% Loosely correlated | +6.08% | ||
| BEAM - SANA | 56% Loosely correlated | +2.31% | ||
| MGTX - SANA | 55% Loosely correlated | +5.44% | ||
More | ||||